I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies. An ''inconvenient'' truth?

Published December 2018 | Version v1

Journal article Metadata-only

1. University Hospital Marburg, Department of Nuclear Medicine, Marburg (Germany)
2. Oncology Institute of Southern Switzerland, Department of Nuclear Medicine and Thyroid Centre, Bellinzona (Switzerland)
3. Papageorgiou Hospital, Academic Department of Nuclear Medicine, Thessaloniki (Greece)
4. Erasus MC, Department of Nuclear Medicine, Rotterdam (Netherlands)
5. St Vincent's Hospital, Department of Nuclear Medicine and Endocrinology, PET-CT Center LINZ, Linz (Austria)
6. University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany)
7. Oncology Institute of Vojvodina, Department of Nuclear Medicine, Sremska Kamenica (Serbia)

no abstract available

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-018-4184-z

Country of Publication: Germany
Country of Input or Organization: Germany
INIS RN: 50004025
Subject category: S62: RADIOLOGY AND NUCLEAR MEDICINE;
Resource subtype / Literary indicator: No Abstract
Descriptors DEI: CARCINOMAS; CLINICAL TRIALS; DELAYED RADIATION EFFECTS; HEMATOLOGY; IODINE 131; RADIATION HAZARDS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RECOMMENDATIONS; THYROID
Descriptors DEC: BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; BIOLOGICAL RADIATION EFFECTS; BODY; DAYS LIVING RADIOISOTOPES; DISEASES; DRUGS; ENDOCRINE GLANDS; GLANDS; HAZARDS; HEALTH HAZARDS; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; MATERIALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIATION EFFECTS; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; TESTING; THERAPY